These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26391562)

  • 1. Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors.
    Kiseljak-Vassiliades K; Xu M; Mills TS; Smith EE; Silveira LJ; Lillehei KO; Kerr JM; Kleinschmidt-DeMasters BK; Wierman ME
    Mol Cell Endocrinol; 2015 Dec; 417():73-83. PubMed ID: 26391562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
    Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
    Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin receptor subtype gene expression in pituitary adenomas.
    Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly.
    Fougner SL; Casar-Borota O; Heck A; Berg JP; Bollerslev J
    Clin Endocrinol (Oxf); 2012 Jan; 76(1):96-102. PubMed ID: 21722151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas.
    Kato M; Inoshita N; Sugiyama T; Tani Y; Shichiri M; Sano T; Yamada S; Hirata Y
    Endocr J; 2012; 59(3):221-8. PubMed ID: 22200580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly.
    Zhang S; Yao S; Chen J; Akter F; Yang J; Zhu D; Zeng A; Chen W; Mao Z; Zhu Y; Wang H
    J Neurosurg; 2024 Apr; 140(4):1019-1028. PubMed ID: 37856412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance spectroscopy may serve as a presurgical predictor of somatostatin analog therapy response in patients with growth hormone-secreting pituitary macroadenomas.
    Hu J; Yan J; Zheng X; Zhang Y; Ran Q; Tang X; Shu T; Shen R; Duan L; Zhang D; Guo Q; Zhang W; Yang H; Li S
    J Endocrinol Invest; 2019 Apr; 42(4):443-451. PubMed ID: 30171531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas.
    Mayr B; Buslei R; Theodoropoulou M; Stalla GK; Buchfelder M; Schöfl C
    Eur J Endocrinol; 2013 Oct; 169(4):391-400. PubMed ID: 23847328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
    Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
    Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
    Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
    J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E-cadherin expression is associated with somatostatin analogue response in acromegaly.
    Venegas-Moreno E; Flores-Martinez A; Dios E; Vazquez-Borrego MC; Ibañez-Costa A; Madrazo-Atutxa A; Japón MA; Castaño JP; Luque RM; Cano DA; Soto-Moreno A
    J Cell Mol Med; 2019 May; 23(5):3088-3096. PubMed ID: 30843342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
    Jaquet P; Saveanu A; Gunz G; Fina F; Zamora AJ; Grino M; Culler MD; Moreau JP; Enjalbert A; Ouafik LH
    J Clin Endocrinol Metab; 2000 Feb; 85(2):781-92. PubMed ID: 10690891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors.
    Greenman Y; Melmed S
    J Clin Endocrinol Metab; 1994 Feb; 78(2):398-403. PubMed ID: 8106629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting Response to Medical Treatment in Acromegaly via Granulation Pattern, Expression of Somatostatin Receptors Type 2 and 5 and E-Cadherin.
    Gliga MC; Chinezu L; Pascanu IM
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction.
    Murabe H; Shimatsu A; Ihara C; Mizuta H; Nakamura Y; Nagata I; Kikuchi H; Nakao K
    J Neuroendocrinol; 1996 Aug; 8(8):605-10. PubMed ID: 8866248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
    Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological markers of somatotroph pituitary neuroendocrine tumors predicting the response to medical treatment.
    Trouillas J; Vasiljevic A; Lapoirie M; Chinezu L; Jouanneau E; Raverot G
    Minerva Endocrinol; 2019 Jun; 44(2):129-136. PubMed ID: 30531694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
    Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
    J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.